The role of exosomes in brain tumors: Mechanisms, diagnosis, and therapeutic prospects

Articles in Press

Document Type : Review Article

Authors

1 University of Al-Ameed -College of Pharmacy, Kerbala, Iraq

2 University of Kerbala -College of Pharmacy, Kerbala, Iraq

3 University of Kerbala -College of Dentistry, Kerbala, Iraq

4 Department of Biophysics, Faculty of Advanced Technologies, University of Mohaghegh Ardabili, Namin, Iran

10.22038/ijbms.2025.88573.19183

Abstract

Cancer remains a leading cause of mortality worldwide, with metastases significantly impacting patient prognosis. Brain metastases (BM) and primary malignant gliomas, such as glioblastoma (GBM), are among the most aggressive forms, with survival rates often below 12 months. GBM alone accounts for 2.5% of cancer-related deaths globally and is a leading cause of mortality in young adults aged 15–34. One of the major challenges in treating brain tumors is the blood-brain barrier (BBB), which limits the delivery of therapeutic agents to the central nervous system (CNS). Exosomes, a subset of extracellular vesicles (EVs), have emerged as promising candidates for overcoming these challenges due to their natural ability to transport bioactive molecules across biological barriers. These nanosized vesicles (30–150 nm) are actively involved in tumor progression, angiogenesis, immune modulation, and drug resistance. Recent studies have highlighted their potential as biomarkers for early cancer detection and as drug delivery vehicles capable of crossing the BBB. Despite their promise, challenges such as large-scale production, efficient cargo loading, and targeted delivery remain critical hurdles to clinical translation. This review explores the role of exosomes in brain malignancies, focusing on their involvement in tumor progression, potential utility as diagnostic biomarkers, and prospective therapeutic applications.

Keywords

Main Subjects

References

1. Proescholdt MA, Schödel P, Doenitz C, Pukrop T, Höhne J, Schmidt NO, et al. The management of brain metastases: Systematic review of neurosurgical aspects. Cancers 2021; 13: 1616-1632.
2.    Oliveira FD, Castanho MA, Neves V. Exosomes and brain metastases: A review on their role and potential applications. Int J Mol Sci 2021; 22: 10899.
3.    Tămaș F, Bălașa R, Manu D, Gyorki G, Chinezu R, Tămaș C, et al. The importance of small extracellular vesicles in the cerebral metastatic process. Int J Mol Sci 2022; 23: 1449-1459.
4.    Tambaro S, Mitra S, Gera R, Linderoth B, Wahlberg LU, Darreh-Shori T, et al. Feasibility and therapeutic potential of local intracerebral encapsulated cell biodelivery of BDNF to App NL-G-F knock-in Alzheimer mice. Alzheimers Res Ther 2023; 15: 137-155.
5.    Fang X, Gong R, Yang D, Li C, Zhang Y, Wang Y, et al. NIR-II light-driven genetically engineered exosome nanocatalysts for efficient phototherapy against glioblastoma. J Am Chem Soc 2024; 146: 15251-15263.
6.    Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020; 367: eaau6977.
7.    Mehryab F, Rabbani S, Shahhosseini S, Shekari F, Fatahi Y, Baharvand H, et al. Exosomes as a next-generation drug delivery system: an update on drug loading approaches, characterization, and clinical application challenges. Acta Biomater 2020; 113: 42-62.
8.    Zhang Y, Lv P, Zhang Q, Xiang W, Jiang X, Guo Z, et al. Exosomal miR-21-5p from glioma-associated mesenchymal stem cells promotes the progression and glycolysis of glioblastoma via PDHA1. Sci Rep 2025; 15: 2320-2334.
9.    Wang Y, Huo Y, Zhao C, Liu H, Shao Y, Zhu C, et al. Engineered exosomes with enhanced stability and delivery efficiency for glioblastoma therapy. J Control Release 2024; 368: 170-183.
10.    Lee H, Bae K, Baek AR, Kwon EB, Kim YH, Nam SW, et al. Glioblastoma-derived exosomes as nanopharmaceutics for improved glioma treatment. Pharmaceutics 2022; 14: 1002-1021.
11.    Yang J, Li Y, Jiang S, Tian Y, Zhang M, Guo S, et al. Engineered brain-targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma. Exploration 2024; 5:20240039.
12.    Pecankova K, Pecherkova P, Gasova Z, Sovova Z, Riedel T, Jäger E, et al. Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome. PLoS One 2022; 17: e0262484.
13.    Chiasserini D, Bijnsdorp I, Bellomo G, Orvietani PL, Piersma SR, Pham TV, et al. Proteomic analysis of extracellular vesicles in cerebrospinal fluid of patients with Alzheimer’s disease. MedRxiv 2020; 2020.02.22.20026609.
14.    Liew FF, Chew BC, Ooi DJ. Wound healing properties of exosomes: a review and modelling of combinatorial analysis strategies. Curr Mol Med 2022; 22: 165-191.
15.    El Fekih R, Hurley J, Tadigotla V, Alghamdi A, Srivastava A, Coticchia C, et al. Discovery and validation of a urinary exosome mRNA signature for the diagnosis of human kidney transplant rejection. J Am Soc Nephrol 2021; 32: 994-1004.
16.    Momen LT, Abdolmaleki A, Asadi A, Akram M. Regeneration and diagnosis of kidney disease using exosomes. Jentashapir J Cell Mol Biol 2021; 12: e120113.
17.    Słyk-Gulewska P, Kondracka A, Kwaśniewska A. MicroRNA as a new bioactive component in breast milk. Noncoding RNA Res 2023; 8: 1-10.
18.    Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-mediated metastasis: Communication from a distance. Dev Cell 2019; 49: 347-360.
19.    Remec Pavlin M, Hurley JH. The ESCRTs: Converging on mechanism. J Cell Sci 2020; 133: jcs240333.
20.    Portilla Y, Mulens-Arias V, Paradela A, Ramos-Fernández A, Pérez-Yagüe S, Morales MP, et al. The surface coating of iron oxide nanoparticles drives their intracellular trafficking and degradation in endolysosomes differently depending on the cell type. Biomaterials 2022; 281: 121365.
21.    Zhao S, Wang Q, Ni K, Zhang P, Liu Y, Xie J, et al. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients. Front Immunol 2023; 14: 1263329.
22.    Yue B, Yang H, Wang J, Ru W, Wu J, Huang Y, et al. Exosome biogenesis, secretion and function of exosomal miRNAs in skeletal muscle myogenesis. Cell Prolif 2020; 53: e12857.
23.    Gioseffi A, Edelmann MJ, Kima PE. Intravacuolar pathogens hijack host extracellular vesicle biogenesis to secrete virulence factors. Front Immunol 2021; 12: 662944.
24.    Huang Z, Keramat S, Izadirad M, Chen ZS, Soukhtanloo M. The potential role of exosomes in the treatment of brain tumors: recent updates and advances. Front Oncol 2022; 12: 869929.
25.    Sun C, Wang P, Dong W, Liu H, Sun J, Zhao L. LncRNA PVT1 promotes exosome secretion through YKT6, RAB7, and VAMP3 in pancreatic cancer. Aging (Albany NY) 2020; 12: 10427-10440.
26.    Feix AS, Tabaie EZ, Singh AN, Wittenberg NJ, Wilson EH, Joachim A. An in-depth exploration of the multifaceted roles of extracellular vesicles in pathogenic single-cell microorganisms. Microbiol Mol Biol Rev 2024; 88: e00037-24.
27.    Bielska E, Harrison PJ. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018;7:1535750.
28.    Sidhom K, Obi PO, Saleem AJ. A review of exosomal isolation methods: is size exclusion chromatography the best option? Int J Mol Sci 2020;21:6466-6484.
29.    Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol 2015; 129: 849-865.
30.    Yadav R, Singh AV, Kushwaha S, Chauhan DS. Emerging role of exosomes as a liquid biopsy tool for diagnosis, prognosis, and monitoring treatment response of communicable and non-communicable diseases. Indian J Med Res 2024; 159: 163-180.
31.    Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, et al. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro Oncol 2021; 23: 264-276.
32.    Bouzari B, Mohammadi S, Bokov DO, Krasnyuk II, Hosseini-Fard SR, Hajibaba M, et al. Angioregulatory role of miRNAs and exosomal miRNAs in glioblastoma pathogenesis. Biomed Pharmacother 2022; 148: 112760.
33.    Hong S, You JY, Paek K, Park J, Kang SJ, Han EH, et al. Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment. Theranostics 2021; 11: 9687-9706.
34.    Nie M, Huang D, Chen G, Zhao Y, Sun L. Bioadhesive microcarriers encapsulated with IL-27 high expressive MSC extracellular vesicles for inflammatory bowel disease treatment. Adv Sci 2023; 10: 2303349.
35.    Finbloom JA, Sousa F, Stevens MM, Desai TA. Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. Adv Drug Deliv Rev 2020; 167: 89-108.
36.    Ramalho MJ, Loureiro JA, Coelho MA, Pereira MC. Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma. Pharmaceutics 2022; 14: 279-309.
37.    Saint-Pol J, Gosselet F, Duban-Deweer S, Pottiez G, Karamanos Y. Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells 2020; 9: 851-863.
38.    Chen CC, Liu L, Ma F, Wong CW, Guo XE, Chacko JV, et al. Elucidation of exosome migration across the blood-brain barrier model in vitro. Cell Mol Bioeng 2016; 9: 509-529.
39.    Banks WA, Sharma P, Bullock KM, Hansen KM, Ludwig N, Whiteside TL. Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation. Int J Mol Sci 2020; 21: 4407-4427.
40.    Tang B, Zeng W, Song LL, Wang HM, Qu LQ, Lo HH, et al. Extracellular vesicle delivery of neferine for the attenuation of neurodegenerative disease proteins and motor deficit in an Alzheimer’s disease mouse model. Pharmaceuticals 2022; 15: 83-105.
41.    Rehman FU, Liu Y, Zheng M, Shi B. Exosomes-based strategies for brain drug delivery. Biomaterials 2023; 293: 121949.
42.    Allegra A, Petrarca C, Di Gioacchino M, Casciaro M, Musolino C, Gangemi S. Exosome-mediated therapeutic strategies for management of solid and hematological malignancies. Cells 2022; 11: 1128-1160.
43.    Steeg PS. The blood-tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol 2021; 18: 696-714.
44.    Fanelli GN, Grassini D, Ortenzi V, Pasqualetti F, Montemurro N, Perrini P, et al. Decipher the glioblastoma microenvironment: The first milestone for new groundbreaking therapeutic strategies. Genes 2021; 12: 445-468.
45.    Wang R, Liang Q, Zhang X, Di Z, Wang X, Di L. Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment. Colloids Surf B Biointerfaces 2022; 215: 112505.
46.    Mardi N, Salahpour-Anarjan F, Nemati M, Baher NS, Rahbarghazi R, Zarebkohan A. Exosomes: multifaceted nanoplatform for targeting brain cancers. Cancer Lett 2023; 557: 216077.
47.    Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther 2023; 8: 124-143.
48.    Movahedpour A, Khatami SH, Khorsand M, Salehi M, Savardashtaki A, Mirmajidi SH, et al. Exosomal noncoding RNAs: Key players in glioblastoma drug resistance. Mol Cell Biochem 2021; 476: 4081-4092.
49.    Liu X, Guo Q, Gao G, Cao Z, Guan Z, Jia B, et al. Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. J Nanobiotechnology 2023; 21: 45-69.
50.    Li X, Wang N, Leng H, Yuan H, Xu L. Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma. Metab Brain Dis 2022; 37: 2979-2993.
51.    Jin P, Bai X. Exploring the roles and clinical potential of exosome-derived noncoding RNAs in glioma. IBRO Neurosci Rep 2025; 18: 323-337.
52.    Yang L, Niu Z, Ma Z, Wu X, Vong CT, Li G, et al. Exploring the clinical implications and applications of exosomal miRNAs in gliomas: A comprehensive study. Cancer Cell Int 2024; 24:323-340. 
53.    Ramezani A, Rahnama M, Mahmoudian F, Shirazi F, Ganji M, Bakhshi S, et al. Current understanding of the exosomes and their associated biomolecules in glioblastoma biology, clinical treatment, and diagnosis. J Neuroimmune Pharmacol 2025; 20: 1-30.
54.    Tan WQ, Yuan L, Wu XY, He CG, Zhu SC, Ye M. Exosome-delivered circular RNA DLGAP4 induces chemoresistance via miR-143-HK2 axis in neuroblastoma. Cancer Biomark 2022; 34: 375-384.
55.    Degli Esposti C, Iadarola B, Maestri S, Beltrami C, Lavezzari D, Morini M, et al. Exosomes from plasma of neuroblastoma patients contain double-stranded DNA reflecting the mutational status of parental tumor cells. Int J Mol Sci 2021; 22: 3667-3686.
56.    Morini M, Raggi F, Bartolucci M, Petretto A, Ardito M, Rossi C, et al. Plasma-derived exosome proteins as novel diagnostic and prognostic biomarkers in neuroblastoma patients. Cells 2023; 12: 2516-2543.
57.    Panachan J, Rojsirikulchai N, Pongsakul N, Khowawisetsut L, Pongphitcha P, Siriboonpiputtana T, et al. Extracellular vesicle-based method for detecting MYCN amplification status of pediatric neuroblastoma. Cancers 2022; 14: 2627-2640.
58.    Nag S, Bhattacharya B, Dutta S, Mandal D, Mukherjee S, Anand K, et al. Clinical theranostics trademark of exosomes in glioblastoma metastasis. ACS Biomater Sci Eng 2023; 9: 5205-5221.
59.    Catelan S, Olioso D, Santangelo A, Scapoli C, Tamanini A, Pinna G, et al. miRNAs in serum exosomes for differential diagnosis of brain metastases. Cancers 2022; 14: 3493-3504.
60.    Yang C, Wu Y, Wang L, Li S, Zhou J, Tan Y, et al. Glioma-derived exosomes hijack the blood-brain barrier to facilitate nanocapsule delivery via LCN2. J Control Release 2022; 345: 537-548.
61.    Huang G, Xu G, Cao Q, Li S, Li H, Zhang X, et al. Role of GPX3+ astrocytes in breast cancer brain metastasis activated by circulating tumor cell exosomes. NPJ Precis Oncol 2025; 9: 64-82.
62.    Ghufran SM, Brown ML, Beierle EA. Role of exosomes in diagnosis, prognostication, and treatment of pediatric solid tumors. Med Treat Oncol 2025; 33: 1-10.
63.    Dhamdhere MR, Spiegelman VS. Extracellular vesicles in neuroblastoma: Role in progression, resistance to therapy, and diagnostics. Front Immunol 2024; 15: 1385875.
64.    Bhavsar SP, Morini MJ. The emerging role of exosomal proteins in neuroblastoma. Front Oncol 2024; 14: 1414063.
65.    Lim J, Kang M, Ahn YH, Cho MS, Lee JH, Kang JL, et al. Comprehensive profiling of serum exosomes by a multi-omics approach reveals potential diagnostic markers for brain metastasis in lung cancer. Cancers 2025; 17: 1929-1948.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 28 December 2025

Files

Share

How to cite

Statistics